Hormones-International Journal of Endocrinology and Metabolism最新文献

{"title":"Quality of life in thyroid cancer survivors with and without permanent hypoparathyroidism.","authors":"Matthias Büttner, Gerasimos Sykiotis, Akram Al-Ibraheem, Monica Pinto, Ioannis Iakovou, Arild Andre Østhus, Eva Hammerlid, Laura Deborah Locati, Eva Maria Gamper, Juan Ignacio Arraras, Susan J Jordan, Naomi Kiyota, Deborah Engesser, Katherine Taylor, Rita Canotilho, Georgios Ioannidis, Olga Husson, Ricardo Ribeiro Gama, Giuseppe Fanetti, Laura Moss, Johanna Inhestern, Guy Andry, Harald Rimmele, Susanne Singer","doi":"10.1007/s42000-025-00654-2","DOIUrl":"https://doi.org/10.1007/s42000-025-00654-2","url":null,"abstract":"<p><strong>Purpose: </strong>Hypoparathyroidism (HypoPT) is one of the most common complications of surgical treatment for thyroid cancer and afflicated patients often report symptoms or impairments in quality of life (QoL). We aimed to investigate differences in various QoL domains between thyroid cancer survivors with and without permanent hypoparathyroidism.</p><p><strong>Methods: </strong>Thyroid cancer survivors with a minimum of 1.5 years post-diagnosis completed the EORTC core questionnaire (EORTC QLQ-C30) and the EORTC thyroid module (QLQ-THY34). Sociodemographic and clinical information were obtained from the patients themselves and their medical charts. Analysis of covariance was used to compare QoL between survivors with and without hypoparathyroidism (adjusting for age, gender, time since diagnosis, and comorbidity).</p><p><strong>Results: </strong>Of the 126 participants, 21 (17%) were diagnosed with permanent HypoPT. There was no evidence of differences regarding any QoL domain between survivors due to hypoparathyroidism. The symptoms with the highest burden for both groups were fatigue (hypoPT: 24.9; non-hypoPT: 32.8; p = 0.151) and insomnia (hypoPT: 22.2; non-hypoPT: 30.8; p = 0.213). Thyroid cancer specific impairments were observed for joint pain (hypoPT: 28.6; non-hypoPT: 34.0; p = 0.480), worry about important others (hypoPT: 25.8; non-hypoPT: 27.9; p = 0.765), exhaustion (hypoPT: 23.8; non-hypoPT: 27.9; p = 0.482), and lacking social support (hypoPT: 36.5; no-hypoPT: 23.0; p = 0.070).</p><p><strong>Conclusion: </strong>The present study appears to show that QoL in thyroid cancer survivors may be unrelated to hypoparathyroidism, further suggesting a more complex relationship between these two aspects.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of sleeve gastrectomy on bone marrow fat in metabolic syndrome patients with and without diabetes: a prospective follow-up study.","authors":"Chenglin Zhao, Qiang Ma, Xinmeng Hou, Yuanyuan Yan, Xiaoyue Cheng, Lizhi Xie, Zhenghan Yang","doi":"10.1007/s42000-025-00660-4","DOIUrl":"https://doi.org/10.1007/s42000-025-00660-4","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate bone marrow fat concentration changes after sleeve gastrectomy in metabolic syndrome patients with and without diabetes.</p><p><strong>Methods: </strong>A total of 58 metabolic syndrome patients (29 metabolic syndrome patients with diabetes (35.10 years ± 6.62) and 29 metabolic syndrome patients without diabetes (35.07 years ± 6.47)) who underwent sleeve gastrectomy received prospective follow-up for 2 years. Echo asymmetry, least square estimation-MRI, and laboratory tests were performed on all patients before and 2 years after surgery. The differences between baseline and end-of-study parameters were analyzed with the paired Student's t test. In addition, the associations of vertebral bone marrow fat concentration (denoted by proton density fat fraction, PDFF) with other variables were determined using multiple linear regression analysis.</p><p><strong>Results: </strong>Bone proton density fat fraction decreased significantly among patients with diabetes (from 38.62 ± 8.01 to 34.54 ± 7.54, P = 0.003) and without diabetes (from 36.82 ± 8.80 to 35.09 ± 8.33, P = 0.011) after sleeve gastrectomy. Among patients with diabetes, multivariable predictors of changes in proton density fat fraction by descending order of standardized coefficient were changes in HbA1c (2.690, P < 0.001), baseline HbA1c (2.354, P < 0.001), changes in insulin (0.627, P < 0.001), changes in low-density lipoprotein cholesterol (0.597, P = 0.013), and changes in C-peptide (-0.664, P = 0.001). Among patients without diabetes, multivariable predictors of changes in proton density fat fraction were changes in low-density lipoprotein cholesterol (1.486, P < 0.001), changes in high-density lipoprotein cholesterol (0.460, P = 0.003), baseline low-density lipoprotein cholesterol (0.438, P = 0.014), changes in triglyceride (0.383, P = 0.007), and changes in total cholesterol (-1.614, P < 0.001).</p><p><strong>Conclusions: </strong>Sleeve gastrectomy may decrease bone marrow fat concentration of MetS patients regardless of diabetes status. Changes in bone marrow fat concentration may be influenced by different factors based on diabetes status.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual dysfunction in male patients with obesity: is it still being overlooked?","authors":"Vahit Can Cavdar, Yagmur Izgi, Feray Akbas","doi":"10.1007/s42000-025-00657-z","DOIUrl":"https://doi.org/10.1007/s42000-025-00657-z","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity has been linked to an elevated susceptibility to development of erectile dysfunction, yet the interplay between sex hormone levels, sexual function, and obesity remains unclear. This study aimed to investigate sexual dysfunction among male patients with obesity and to emphasize the importance of recognizing the problem and pursuing solutions.</p><p><strong>Methods: </strong>A total of 60 patients were included in the study (30 patients from the obesity center and 30 patients without obesity as the control group). Assessment of androgen hormone deficiency and erectile dysfunction was conducted through the implementation of AMS and IIEF-5 tests. The questionnaire includes aspects of medical history, demographic features, and lifestyle factors. Comprehensive measurements included BMI, WC, BP, lipid panel, total/free testosterone, sex-hormone-binding-globulin (SHBG), dehydroepiandrosterone-sulfate (DHEAS), fasting blood glucose (FBG), fasting insulin, and HbA1C levels. Results were evaluated using SPSS.</p><p><strong>Results: </strong>The AMS score in the obesity group was significantly lower compared to the group without obesity. The IIEF-5 score did not exhibit a statistically significant difference between the groups. Testosterone, free testosterone, SHBG, and HDL values were lower in the obesity group compared to the group without obesity.</p><p><strong>Conclusion: </strong>Although conducted in a small sample, our findings strongly indicate a positive correlation between obesity and the risk of moderate to severe ED. Most of the time, this condition goes unarticulated, thereby adversely affecting the quality of life for individuals with obesity. Clinicians should pay more attention to patients experiencing sexual dysfunction, especially those with obesity.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of long-term remnant cholesterol with the incidence of chronic kidney disease in a high-risk population.","authors":"Ping Zhang, Yu-Hong Liu, Wen-Yan Xiong, Yi-Bing Fan, Xiao-Lin Zhu, Kun Zhou, Hui Li","doi":"10.1007/s42000-025-00651-5","DOIUrl":"https://doi.org/10.1007/s42000-025-00651-5","url":null,"abstract":"<p><strong>Background and aims: </strong>Chronic kidney disease (CKD) is creating an ever heavier global health burden with population ageing. This study aimed to examine the longitudinal associations of remnant cholesterol (RC) with CKD morbidity in a large high-risk population (type 2 diabetes and hypertension).</p><p><strong>Methods: </strong>A total of 11,881 participants who participated in annual health examinations from 2021 to 2023 were included in our analysis. The Cox proportional hazards model was performed to analyze the associations of baseline RC, cumulative RC, and variability of RC with CKD morbidity. The cross-lagged panel analysis was used to examine the temporal relationship between RC and renal function.</p><p><strong>Results: </strong>The results of the multivariable-adjusted models showed that higher baseline, cumulative RC, and variability of RC were related to higher risks of developing CKD, the adjusted HR (95% CI) comparing tertile 3 with tertile 1 were 1.26 (95% CI 1.10-1.45), 1.33 (95% CI 1.16-1.52), 1.36 (95% CI 1.20-1.55), respectively. Stratified analysis found that gender did not change these associations. Compared with individuals in the low cumulative and variability RC group, those in the high cumulative and variability RC group had a 1.62 times higher risk of CKD (95% CI: 1.34-1.96). The cross-lagged panel analysis showed that the increase in RC levels may precede the decrease in eGFR.</p><p><strong>Conclusions: </strong>High baseline level, cumulative exposure to RC, and variability of RC are associated with increased CKD risk. Therefore, monitoring RC-related parameters is crucial to delay the occurrence and development of CKD in high-risk populations.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of hemodilution in the inverse association between obesity and testosterone concentrations in men.","authors":"Shiwei Shen, Jingting Yun, Cheng Song, Yun Lu, Zhenhai Shen, Feng Li","doi":"10.1007/s42000-025-00656-0","DOIUrl":"https://doi.org/10.1007/s42000-025-00656-0","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to explore the inverse correlation between obesity and testosterone concentrations in men, with a particular focus on the role of hemodilution in this association. The research question addressed is whether hemodilution, due to increased plasma volume (PV), contributes to the lower testosterone concentrations observed in obese men.</p><p><strong>Methods: </strong>We conducted a retrospective analysis using three datasets with sample sizes of 86, 134, and 446 participants, respectively. Multivariable linear regression models were used to examine the changes in PV, testosterone concentration, and mass across BMI categories, adjusting for age in each dataset and in the pooled data.</p><p><strong>Results: </strong>The study demonstrated a significant inverse correlation between BMI groups and testosterone concentrations across the three datasets, as well as in the pooled data (beta coefficients: -0.024, -0.045, -0.040, -0.043; P < 0.001). Despite this, total testosterone mass remained stable (P > 0.05), suggesting that hemodilution, rather than a reduction in testosterone production, may account for the lower testosterone concentrations in obesity. Adjusted testosterone concentrations for obese participants were calculated using a formula that accounts for the increased PV.</p><p><strong>Conclusion: </strong>Our findings suggest that hemodilution, associated with increased PV in obesity, is a significant factor contributing to the lower testosterone concentrations in obese men. This has implications for the diagnosis and treatment of testosterone deficiency in obesity and underscores the need for adjusted reference ranges. Further research is necessary to validate these findings and to explore their clinical implications.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of COVID-19 pandemic on the incidence, presentation, and management of type 1 diabetes in children and adolescents: a narrative review.","authors":"Irene Papapetrou, Agnieszka Swiecicka","doi":"10.1007/s42000-025-00662-2","DOIUrl":"https://doi.org/10.1007/s42000-025-00662-2","url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is an autoimmune condition affecting approximately 1.5 million children and adolescents worldwide, with an incidence of approximately 2-3% each year and rising. During the recent COVID-19 pandemic, a significant increase in incidence of T1D in children and adolescents was observed in numerous countries worldwide, with an increased number of newly-diagnosed cases presenting with diabetic ketoacidosis. The increased frequency of T1D presenting with diabetic ketoacidosis has been attributed not only to the SARS-CoV-2 virus itself but also to the restrictions imposed by the pandemic. The shift to telemedicine and unwillingness to seek medical care due to fear of infection contributed to delayed diagnosis and more severe disease presentation. Furthermore, the periods of lockdown that were implemented during the pandemic presented multiple challenges for children and adolescents living with T1D and disrupted the management of their condition. Changes in physical activity and diet as well as shortage of medical supplies during that period have been linked to worsening of glycemic control, which were at least partly offset by increased parental involvement and use of telemedicine.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel pathogenic variant of the glucocorticoid receptor gene, causing generalized glucocorticoid resistance: a case report and review of the literature.","authors":"Özge Güngör, Sena Yeral, Büşra Özcan, Duygu Arıcan, Ilgın Yıldırım Şimşir, Haluk Akın, Ayça Aykut, Asude Durmaz","doi":"10.1007/s42000-025-00659-x","DOIUrl":"https://doi.org/10.1007/s42000-025-00659-x","url":null,"abstract":"<p><strong>Purpose: </strong>Generalized glucocorticoid resistance (GGCR) is caused by variants in the NR3C1 gene, which encodes the human glucocorticoid receptor (hGR). To date, 39 pathogenic variants of NR3C1 have been reported, primarily in the ligand-binding domain (LBD). This study presents a novel case of the NR3C1 variant located in the N-terminal domain (NTD) of hGR, highlighting its clinical and molecular significance in glucocorticoid resistance.</p><p><strong>Case presentation: </strong>The patient was a 21-year-old woman presenting with chronic fatigue, irregular menstrual cycles, and osteopenia, though without any clinical signs of Cushing's syndrome. She underwent a standard evaluation of the hypothalamic-pituitary-adrenal (HPA) axis. Endocrinological tests revealed elevated levels of ACTH, morning serum cortisol, aldosterone, DHEAS, 11-deoxycortisol, pregnenolone, and corticosterone, as well as increased urinary-free cortisol excretion. The low-dose dexamethasone suppression test (LDDST) showed suppression of cortisol levels. Molecular analysis via Whole Exome Sequencing (WES) identified a novel heterozygous pathogenic variant, c.220 C > T (p.Gln74Ter), in the NR3C1 gene. This confirmed the diagnosis of glucocorticoid resistance syndrome.</p><p><strong>Conclusion: </strong>This case contributes to expanding the mutational spectrum of NR3C1 in glucocorticoid resistance syndrome, supporting more accurate diagnosis and genetic counseling for affected individuals.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone replacement therapy in heart failure: A systematic review of randomized controlled trials.","authors":"Nikolaos Theodorakis, Magdalini Kreouzi, Christos Hitas, Dimitrios Anagnostou, Zoi Kollia, Georgia Vamvakou, Maria Nikolaou","doi":"10.1007/s42000-025-00658-y","DOIUrl":"https://doi.org/10.1007/s42000-025-00658-y","url":null,"abstract":"<p><strong>Introduction: </strong>Heart failure (HF), a leading cause of morbidity and mortality, is characterized by a complex pathophysiology involving neurohormonal activation, metabolic dysregulation, and multiple hormonal deficiency syndrome (MHDS). MHDS is common in HF, affecting up to 90% of patients, and is associated with worse outcomes. This systematic review aims to evaluate the efficacy and safety of testosterone replacement therapy (TRT) in the management of HF.</p><p><strong>Methods: </strong>We conducted a comprehensive search of PubMed, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) examining TRT in HF patients up to September 15, 2024. Studies were included if they involved human subjects aged 18 or older with a confirmed diagnosis of HF and had a follow-up period of at least 4 weeks. We excluded reviews, animal studies, observational studies, and trials without randomization.</p><p><strong>Results: </strong>Our search yielded 653 records, of which 12 studies met the inclusion criteria. Key findings include significant improvements in muscle strength and aerobic capacity as well as increases in lean muscle mass and decreases in fat mass in certain trials. Additionally, improvements in insulin sensitivity and shortening of the QT interval were reported. TRT did not consistently affect blood pressure, lipid profiles, or heart rate, nor did it lead to any serious adverse effects.</p><p><strong>Discussion: </strong>While TRT has demonstrated potential benefits in HF patients, particularly in improving physical function and metabolic profiles, the current evidence is limited by small sample sizes and short follow-up periods. Larger event-driven RCTs evaluating hard endpoints are needed to determine whether TRT should be integrated into standard HF therapies.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between urinary iodine concentration and all-cause mortality in individuals with diabetes: An analysis of National Health and Nutrition Examination Survey 2005 - 2018.","authors":"Xin Lai, Leihua Zhang","doi":"10.1007/s42000-025-00653-3","DOIUrl":"https://doi.org/10.1007/s42000-025-00653-3","url":null,"abstract":"<p><strong>Background: </strong>Urinary iodine concentration (UIC) is related to prediabetes and diabetes; nevertheless, there is still a dearth of data about the association of UIC with all-cause mortality in diabetics.</p><p><strong>Objective: </strong>To investigate the connection between UIC and all-cause mortality in diabetics.</p><p><strong>Methods: </strong>Data from NHANES, collected on adult Americans between 2005 and 2018, were used in this investigation. The associations between ln-transformed creatinine-adjusted UIC (urinary iodine/creatinine, UI/Cr) and all-cause mortality in diabetics, as well as in older diabetics with a history of thyroid disease, were analyzed using Cox proportional hazards models and survival curve analysis. Subgroup analyses and interaction tests were conducted to examine variables affecting the association between ln(UI/Cr) and all-cause mortality in people with diabetes. Lastly, the effect of smoking on this association was tested by using restricted cubic spline (RCS).</p><p><strong>Results: </strong>A total of 2,141 participants were included in this study. ln(UI/Cr) was significantly associated with a higher risk of all-cause mortality in diabetics in the unadjusted model (HR= 1.38, 95% CI: 1.20 - 1.58, P<0.001), but this association lost significance when confounding variables were considered (P> 0.05). Subgroup analysis revealed that Mexican-Americans and females had a stronger positive connection (P<0.05) between ln(UI/Cr) and the risk of all-cause mortality among diabetics. There was a significant correlation between ln(UI/Cr) and mortality in female smokers with diabetes (95% CI: 1.16 - 2.18, P=0.004). The RCS analysis demonstrated a significant non-linear relationship (P-non-linear= 0.0131). ln(UI/Cr) was significantly and positively associated with all-cause mortality in elderly diabetic individuals with a history of thyroid disease (HR= 1.38, 95% CI: 1.01 - 1.87, P=0.042).</p><p><strong>Conclusion: </strong>In American individuals with diabetes, our research validates the association between UI/Cr and all-cause mortality. This correlation might offer additional dietary suggestions for the management of individuals with diabetes.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatostatin and N-acetylcysteine on testicular damage triggered by ischemia reperfusion: cellular protection and antioxidant effects.","authors":"Enver Ciftel, Tolga Mercantepe, Serpil Ciftel, Sibel Mataracı Karakas, Riza Aktepe, Adnan Yilmaz, Filiz Mercantepe","doi":"10.1007/s42000-025-00650-6","DOIUrl":"https://doi.org/10.1007/s42000-025-00650-6","url":null,"abstract":"<p><p>Ischemia-reperfusion (I/R) injury is a significant cause of testicular damage, leading to infertility and other reproductive dysfunctions. Antioxidant therapies have emerged as a potential intervention to mitigate oxidative stress and cellular damage. This study investigates the effects of somatostatin (SST) and N-acetylcysteine (NAC) on testicular damage induced by I/R, focusing on their antioxidant and cellular protective effects. Twenty-four male rats were divided into four groups, as follows: sham operated, I/R injury, I/R + somatostatin treatment, and I/R + NAC treatment. A testicular I/R injury was induced surgically, followed by either SST or NAC administration. Testicular tissues were assessed histopathologically using hematoxylin and eosin staining and employing Johnson's biopsy scoring. Immunohistochemical analyses were performed for caspase- 3, 8-hydroxy- 2'-deoxyguanosine (8-OHdG), testis-specific histone 2B, and testosterone to evaluate apoptosis, oxidative DNA damage, cellular proliferation, and steroidogenesis, respectively. Serum levels of testosterone and follicle-stimulating hormone (FSH) were measured by biochemical analysis. The results showed that both SST and NAC treatments significantly ameliorated histopathological damage and reduced the levels of caspase- 3 and 8-OHdG, indicating reduced apoptosis and oxidative DNA damage. Furthermore, increased testis-specific histone 2B positivity suggested enhanced cellular proliferation. Notably, administration of SST decreased testosterone positivity in the testis, whereas NAC treatment increased it. However, no significant differences in serum testosterone levels were observed between the NAC and SST groups. In addition, serum FSH levels of the I/R + SST group were found to be significantly higher than those of the control group. SST and NAC exhibit protective effects against testicular damage induced by I/R, as evidenced by their antioxidant and anti-apoptotic properties. The differential impact on testosterone positivity in the testis tissue highlights distinct underlying mechanisms, warranting further investigation. Despite these promising findings, the lack of significant changes in serum hormone levels calls for additional studies to fully elucidate the therapeutic potential and mechanistic pathways of SST and NAC in the context of testicular I/R injury.</p>","PeriodicalId":50399,"journal":{"name":"Hormones-International Journal of Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}